Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (798)	3/23/2004 4:20:40 PM
From: Icebrg	Read Replies (2) \| Respond to of 2240

AMGEN ANNOUNCES POSITIVE HUMAX-IL15 INTERIM PHASE II DATA Summary: Amgen presented an interim analysis of HuMax-IL15 Phase II data at its R&D Day today. HuMax-IL15 shows significant response compared to placebo in rheumatoid arthritis study. Amgen now designates the product AMG 714. Copenhagen, Denmark; March 23, 2004 – Genmab A/S (CSE: GEN) announced today that Amgen, Inc. released positive interim data from the ongoing HuMax-IL15/AMG 714 Phase II study in rheumatoid arthritis (RA) during their R&D Day meeting in New York City today. The interim analysis covered 110 patients and showed a significant difference between treated patients and those in the placebo group. Patients in the study received HuMax-IL15/AMG 714 or placebo every other week for 12 weeks. Dose levels included placebo, 40 mg, 80 mg, 160 mg or 280 mg with the primary endpoint at week 14. Responses were measured at weeks 4, 8, 12, and 14 and the analysis was pooled so that data from patients in all dose groups was presented together. Amgen also discussed previously disclosed pre-clinical data covering psoriasis and the possibility that HuMax-IL15/AMG 714 may be useful in other indications than RA and may also be useful in combination therapies. HuMax-IL15 has been safe and well tolerated in clinical trials to date with no dose limiting toxicities. In addition, currently available pharmacokinetic data supports dosing every other week. Amgen is adding patients to the study with a goal of finishing the Phase II study in 2004. “This positive Phase II data helps confirm the potential of HuMax-IL15 in rheumatoid arthritis,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. A webcast of the event can be seen at the Amgen website www.amgen.com by clicking on Investors, then on Amgen Events. HuMax-IL15/AMG 714 has been developed under an agreement with Amgen. Amgen has taken responsibility for further development of HuMax-IL15, which they now designate AMG 714.